No Increased Risk Of Treatment-Induced Augmentation In Restless Legs Syndrome Demonstrated In Long-Term Placebo-Controlled Study With Mirapexin Sifrol
New facts presented at the 61st Annual Meeting of the American School of Neurology (AAN), in Seattle, U.S.A. exhibit that augmentation did not significantly differ in RLS patients treated with Mirapexin® /Sifrol® (pramipexole*) versus the group receiving placebo.1Augmentation, i.e. the worsening of RLS symptoms due to pharmacological treatment, has been often observed in patients treated with levodopa, a dopaminergic agent sometimes used to treat RLS.2-4 Existing info for pramipexole, a non-ergot dopamine agonist, suggested that augmentation is less frequent and less severe than with levodopa, 3 however, until now there had been no well designed study to compare the frequency of augmentation under pramipexole versus placebo.
Scientists from Queen Mary, University of London corner discovered a new protein complex operating in fruit fly circadian clocks, which may as well corrective to govern our own organic clocks. Circadian clocks are brainwork to have evolved to enable organisms to match their behaviour to particular time slots during the 24 day day. They are synchronised with our surrounding environment via everyday light or temperature cycles. Professor Ralf Stanewsky and his group from Queen Mary's School of Biological and Chemical Sciences study the circadian clocks of Drosophila, a type of fruit fly. The flies' body-clocks are regulated by two proteins called Time (PER) and Timeless (TIM).
Stroke victims tend to end worse whether they further get diagnosed or undiagnosed obstructive sleep apnea prior to having the stroke, according to a recite presented Apr 28, 2009, at the American Institution of Neurology (AAN) annual concourse in Seattle. Latha Stead, M.D., professor and chair of the Branch of Emergency Medicine at the University of Rochester Medical Center, and professor of Neurosurgery, reported the findings at AAN, along with several other stroke studies measuring the factors that govern to a impecunious prognosis. "We discern that obstructive sleep apnea has been linked to a multitude of cardiovascular problems, even it is concerning that the vast majority of cases carry on undiagnosed, " Stead said.
A drug widely used to treat seizures and anxiety appears to be an competent treatment for restless legs syndrome (RLS) and helps people with the disorder gratify a exceeding night's sleep, according to a scan that testament be presented as factor of the Late-breaking Science Programme at the American College of Neurology's 61st Annual Assemblage in Seattle, April 25 - May 2, 2009. RLS affects up to one in ten people. The 12-week study involved 58 family with RLS. Of the group, 30 people received the drug pregabalin and the rest received placebo. Sleep studies were performed at the induction and end of the research. Researchers fashion almost two-thirds of the individuals who took pregabalin had no RLS symptoms while taking the drug.
A peruse in the May 1 affair of the chronicle SLEEP suggests that babies born to mothers with depression are more likely to suffer from denoting sleep disturbances at 2 weeks postpartum that continue until 6 months of age. Findings of the interpret are of particular importance, as sleep disturbances in childhood may result in increased risk for developing early-onset depression in childhood. Results indicate that infants born to mothers with depression had significant sleep disturbances compared to low-risk infants; the high-risk group had an day longer nocturnal sleep latency, shorter sleep episodes and lower sleep efficiency than infants who were born to mothers without depression.